| NCT03589768 |
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants |
https://ClinicalTrials.gov/show/NCT03589768 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-07-01 |
| NCT03824093 |
High and Low Resource Interventions to Promote HPV Vaccines |
https://ClinicalTrials.gov/show/NCT03824093 |
Enrolling by invitation |
Children’s Mercy Hospital Kansas City |
2019-12-31 |
| NCT03311659 |
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals’ Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects |
https://ClinicalTrials.gov/show/NCT03311659 |
Completed |
GlaxoSmithKline |
2018-08-31 |
| NCT02907216 |
Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals’ Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants |
https://ClinicalTrials.gov/show/NCT02907216 |
Completed |
GlaxoSmithKline |
2017-05-29 |
| NCT02858440 |
A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia |
https://ClinicalTrials.gov/show/NCT02858440 |
Completed |
GlaxoSmithKline |
2017-10-24 |
| NCT02853929 |
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexaâ„¢ in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery |
https://ClinicalTrials.gov/show/NCT02853929 |
Completed |
GlaxoSmithKline |
2019-03-19 |
| NCT02817451 |
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants |
https://ClinicalTrials.gov/show/NCT02817451 |
Completed |
Sanofi |
2019-02-22 |
| NCT02673255 |
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program |
https://ClinicalTrials.gov/show/NCT02673255 |
Completed |
Biomat USA, Inc. |
2019-07-29 |
| NCT02640404 |
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam |
https://ClinicalTrials.gov/show/NCT02640404 |
Completed |
Sanofi |
2016-12-05 |
| NCT02587520 |
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02587520 |
Completed |
Sanofi |
2017-02-21 |
| NCT02428491 |
Immunogenicity and Safety of Sanofi Pasteur’s Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth |
https://ClinicalTrials.gov/show/NCT02428491 |
Completed |
Sanofi |
2017-01-11 |
| NCT02422264 |
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery |
https://ClinicalTrials.gov/show/NCT02422264 |
Completed |
GlaxoSmithKline |
2018-03-07 |
| NCT02377349 |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Pregnant Women |
https://ClinicalTrials.gov/show/NCT02377349 |
Completed |
GlaxoSmithKline |
2017-08-14 |
| NCT02274285 |
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants |
https://ClinicalTrials.gov/show/NCT02274285 |
Completed |
Sanofi |
2016-05-28 |
| NCT02118961 |
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents |
https://ClinicalTrials.gov/show/NCT02118961 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2014-08-31 |
| NCT02096263 |
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants |
https://ClinicalTrials.gov/show/NCT02096263 |
Completed |
GlaxoSmithKline |
2015-02-06 |
| NCT02094833 |
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants |
https://ClinicalTrials.gov/show/NCT02094833 |
Completed |
Sanofi |
2016-04-30 |
| NCT02089347 |
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old |
https://ClinicalTrials.gov/show/NCT02089347 |
Completed |
Sanofi |
2014-09-30 |
| NCT01311557 |
Study of Adacel® Vaccine Administered to Persons 10 Years of Age |
https://ClinicalTrials.gov/show/NCT01311557 |
Completed |
Sanofi |
2011-11-30 |
| NCT01309646 |
Immunogenicity and Safety of GlaxoSmithKline Biologicals’ Infanrixâ„¢-IPV+Hib Vaccine |
https://ClinicalTrials.gov/show/NCT01309646 |
Completed |
GlaxoSmithKline |
2012-02-24 |
| NCT01294605 |
Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) |
https://ClinicalTrials.gov/show/NCT01294605 |
Completed |
GlaxoSmithKline |
2004-09-30 |
| NCT01287949 |
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older |
https://ClinicalTrials.gov/show/NCT01287949 |
Completed |
Sanofi |
2012-05-31 |
| NCT01277705 |
Comparison of GSK Biologicals’ Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® |
https://ClinicalTrials.gov/show/NCT01277705 |
Completed |
GlaxoSmithKline |
2002-04-30 |
| NCT02040636 |
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis |
https://ClinicalTrials.gov/show/NCT02040636 |
Completed |
Sanofi |
2000-05-31 |
| NCT01993173 |
Sanofi Pasteur’s Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. |
https://ClinicalTrials.gov/show/NCT01993173 |
Completed |
Sanofi |
2014-02-28 |
| NCT01988857 |
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Healthy Vietnamese Children |
https://ClinicalTrials.gov/show/NCT01988857 |
Completed |
GlaxoSmithKline |
2014-05-10 |
| NCT01983540 |
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination |
https://ClinicalTrials.gov/show/NCT01983540 |
Completed |
Sanofi |
2015-06-30 |
| NCT01948193 |
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth |
https://ClinicalTrials.gov/show/NCT01948193 |
Completed |
Sanofi |
2014-12-31 |
| NCT01933776 |
Study of the Tdap Combined Vaccine (ADACELâ„¢) as a Booster Dose in Healthy Adults and Children in China |
https://ClinicalTrials.gov/show/NCT01933776 |
Completed |
Sanofi |
2013-11-30 |
| NCT01926015 |
Immunogenicity and Safety of Concomitant Administration of RotaTeqâ„¢ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) |
https://ClinicalTrials.gov/show/NCT01926015 |
Completed |
Merck Sharp & Dohme Corp. |
2014-06-06 |
| NCT01917357 |
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject |
https://ClinicalTrials.gov/show/NCT01917357 |
Completed |
Crucell Holland BV |
2014-04-30 |
| NCT01897402 |
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT01897402 |
Completed |
JN-International Medical Corporation |
2014-05-31 |
| NCT01896596 |
Hepatitis B Vaccination in Infants |
https://ClinicalTrials.gov/show/NCT01896596 |
Completed |
Public Health England |
2017-04-30 |
| NCT01878435 |
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya |
https://ClinicalTrials.gov/show/NCT01878435 |
Completed |
Johns Hopkins Bloomberg School of Public Health |
2016-02-29 |
| NCT04398706 |
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants |
https://ClinicalTrials.gov/show/NCT04398706 |
Recruiting |
Sanofi |
2022-12-31 |
| NCT01738477 |
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Previously Boosted Young Adults |
https://ClinicalTrials.gov/show/NCT01738477 |
Completed |
GlaxoSmithKline |
2014-04-02 |
| NCT01711645 |
Tdap Vaccine in Post-Partum Women |
https://ClinicalTrials.gov/show/NCT01711645 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-08-28 |
| NCT01689324 |
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents |
https://ClinicalTrials.gov/show/NCT01689324 |
Completed |
Sanofi |
2012-11-30 |
| NCT01659996 |
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age |
https://ClinicalTrials.gov/show/NCT01659996 |
Completed |
Sanofi |
2014-11-30 |
| NCT01629589 |
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents |
https://ClinicalTrials.gov/show/NCT01629589 |
Completed |
Sanofi |
2013-03-31 |
| NCT01577732 |
Safety of GSK Biologicals’ Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers |
https://ClinicalTrials.gov/show/NCT01577732 |
Completed |
GlaxoSmithKline |
2013-04-09 |
| NCT01546909 |
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE |
https://ClinicalTrials.gov/show/NCT01546909 |
Completed |
Sanofi |
2012-12-31 |
| NCT01529645 |
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years |
https://ClinicalTrials.gov/show/NCT01529645 |
Completed |
Novartis |
2012-07-31 |
| NCT01519713 |
Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects |
https://ClinicalTrials.gov/show/NCT01519713 |
Completed |
Sanofi |
2012-09-30 |
| NCT01491087 |
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China |
https://ClinicalTrials.gov/show/NCT01491087 |
Completed |
Sanofi |
2012-07-31 |
| NCT01470287 |
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age |
https://ClinicalTrials.gov/show/NCT01470287 |
Completed |
Novartis |
2012-04-30 |
| NCT01457560 |
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine |
https://ClinicalTrials.gov/show/NCT01457560 |
Completed |
GlaxoSmithKline |
2001-04-30 |
| NCT01457547 |
Comparison of Immunogenicity and Reactogenicity of INFANRIXâ„¢ HEXA and HEXAVACâ„¢ Vaccines as a Primary Vaccination Course |
https://ClinicalTrials.gov/show/NCT01457547 |
Completed |
GlaxoSmithKline |
2005-05-31 |
| NCT01457508 |
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately |
https://ClinicalTrials.gov/show/NCT01457508 |
Completed |
GlaxoSmithKline |
2000-03-31 |
| NCT01457495 |
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly |
https://ClinicalTrials.gov/show/NCT01457495 |
Completed |
GlaxoSmithKline |
1999-09-30 |
| NCT01453998 |
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744) |
https://ClinicalTrials.gov/show/NCT01453998 |
Completed |
GlaxoSmithKline |
2012-11-12 |
| NCT01449812 |
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals’ IPV (Poliorixâ„¢) and DTPa/Hib (Infanrix+Hibâ„¢) Vaccine |
https://ClinicalTrials.gov/show/NCT01449812 |
Completed |
GlaxoSmithKline |
2012-01-16 |
| NCT01444781 |
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexaâ„¢ and Prevenarâ„¢ in Healthy Infants |
https://ClinicalTrials.gov/show/NCT01444781 |
Completed |
Sanofi |
2013-04-30 |
| NCT01437423 |
Regulatory Post-Marketing Surveillance Study for TETRAXIMâ„¢ |
https://ClinicalTrials.gov/show/NCT01437423 |
Completed |
Sanofi |
2015-11-30 |
| NCT01439165 |
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose |
https://ClinicalTrials.gov/show/NCT01439165 |
Completed |
Sanofi |
2015-12-31 |
| NCT01362517 |
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B |
https://ClinicalTrials.gov/show/NCT01362517 |
Completed |
Crucell Holland BV |
2010-07-31 |
| NCT01362322 |
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents |
https://ClinicalTrials.gov/show/NCT01362322 |
Completed |
GlaxoSmithKline |
2012-09-03 |
| NCT01358825 |
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ |
https://ClinicalTrials.gov/show/NCT01358825 |
Completed |
GlaxoSmithKline |
2011-07-31 |
| NCT01357720 |
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination |
https://ClinicalTrials.gov/show/NCT01357720 |
Completed |
Crucell Holland BV |
2011-09-30 |
| NCT01353703 |
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals’ Infanrix Hexaâ„¢ (DTPa-HBV-IPV/Hib) Vaccine |
https://ClinicalTrials.gov/show/NCT01353703 |
Completed |
GlaxoSmithKline |
2013-02-25 |
| NCT01346293 |
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age |
https://ClinicalTrials.gov/show/NCT01346293 |
Completed |
Sanofi |
2013-05-31 |
| NCT01323959 |
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults |
https://ClinicalTrials.gov/show/NCT01323959 |
Completed |
GlaxoSmithKline |
2012-03-01 |
| NCT00452686 |
Study to Assess Safety & Immunogenicity of GSK Biologicals’ Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine |
https://ClinicalTrials.gov/show/NCT00452686 |
Completed |
GlaxoSmithKline |
NA |
| NCT04238975 |
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT04238975 |
Recruiting |
Green Cross Corporation |
2021-02-28 |
| NCT04177485 |
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda |
https://ClinicalTrials.gov/show/NCT04177485 |
Completed |
Centers for Disease Control and Prevention |
2017-12-04 |
| NCT04099303 |
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . |
https://ClinicalTrials.gov/show/NCT04099303 |
Recruiting |
CanSino Biologics Inc. |
2020-12-20 |
| NCT04075175 |
Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT04075175 |
Completed |
MassBiologics |
2019-10-07 |
| NCT03998215 |
Diphtheria Vaccination in Adolescents With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03998215 |
Completed |
Medical University of Warsaw |
2015-01-01 |
| NCT03950986 |
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System |
https://ClinicalTrials.gov/show/NCT03950986 |
Completed |
Atlanta VA Medical Center |
2019-05-30 |
| NCT03931239 |
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks |
https://ClinicalTrials.gov/show/NCT03931239 |
Completed |
Vabiotech |
2018-06-30 |
| NCT03891758 |
Confirmatory Study of BK1310 in Healthy Infants |
https://ClinicalTrials.gov/show/NCT03891758 |
Active, not recruiting |
Mitsubishi Tanabe Pharma Corporation |
2019-09-18 |
| NCT03552445 |
Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT03552445 |
Completed |
Korea University Guro Hospital |
2016-04-30 |
| NCT00835237 |
Evaluation of GlaxoSmithKline Biologicals’ Boostrix® Vaccine in Comparison With Decavacâ„¢ Vaccine. |
https://ClinicalTrials.gov/show/NCT00835237 |
Completed |
GlaxoSmithKline |
2009-07-23 |
| NCT01267058 |
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults |
https://ClinicalTrials.gov/show/NCT01267058 |
Completed |
GlaxoSmithKline |
1998-02-28 |
| NCT01262924 |
Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine |
https://ClinicalTrials.gov/show/NCT01262924 |
Completed |
GlaxoSmithKline |
1998-12-31 |
| NCT01249183 |
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old |
https://ClinicalTrials.gov/show/NCT01249183 |
Completed |
Sanofi |
2011-09-30 |
| NCT01248884 |
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744) |
https://ClinicalTrials.gov/show/NCT01248884 |
Completed |
GlaxoSmithKline |
2012-01-05 |
| NCT01245049 |
Immunogenicity and Safety of GSK Biologicals’ Boostrix Polio Vaccine in 3 and 4-year-old Children |
https://ClinicalTrials.gov/show/NCT01245049 |
Completed |
GlaxoSmithKline |
2012-03-27 |
| NCT01214889 |
Study of PENTAXIMâ„¢ Vaccine Versus TETRAXIMâ„¢ Vaccine Given With ACTHIBâ„¢ Vaccine in South Korean Infants. |
https://ClinicalTrials.gov/show/NCT01214889 |
Completed |
Sanofi |
2011-11-30 |
| NCT01177722 |
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenarâ„¢ and Rotarixâ„¢ in Healthy Latin American Infants |
https://ClinicalTrials.gov/show/NCT01177722 |
Completed |
Sanofi |
2011-10-31 |
| NCT01171989 |
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine Administered as a Booster Dose |
https://ClinicalTrials.gov/show/NCT01171989 |
Completed |
GlaxoSmithKline |
2010-12-03 |
| NCT01147900 |
Evaluation of Boostrixâ„¢10 Years After Previous Booster Vaccination |
https://ClinicalTrials.gov/show/NCT01147900 |
Completed |
GlaxoSmithKline |
2012-05-08 |
| NCT01137435 |
Post Marketing Surveillance for ADACELâ„¢ in South Korea |
https://ClinicalTrials.gov/show/NCT01137435 |
Completed |
Sanofi |
2016-03-31 |
| NCT01125527 |
Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children |
https://ClinicalTrials.gov/show/NCT01125527 |
Completed |
Novartis |
2009-10-31 |
| NCT01106092 |
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers |
https://ClinicalTrials.gov/show/NCT01106092 |
Completed |
GlaxoSmithKline |
2010-09-02 |
| NCT01090453 |
Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine in Healthy Infants |
https://ClinicalTrials.gov/show/NCT01090453 |
Completed |
GlaxoSmithKline |
2011-10-11 |
| NCT01086423 |
Immunogenicity and Safety Study of GSK Biologicals’ Infanrix-IPV+Hibâ„¢ Vaccine |
https://ClinicalTrials.gov/show/NCT01086423 |
Completed |
GlaxoSmithKline |
2010-11-19 |
| NCT01062477 |
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants |
https://ClinicalTrials.gov/show/NCT01062477 |
Completed |
Sanofi |
2011-09-30 |
| NCT01044316 |
Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China |
https://ClinicalTrials.gov/show/NCT01044316 |
Completed |
Novartis |
2010-07-31 |
| NCT01040052 |
A Study to Assess the Safety of Adacel® Vaccine |
https://ClinicalTrials.gov/show/NCT01040052 |
Completed |
Sanofi |
2010-02-28 |
| NCT01033877 |
Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults |
https://ClinicalTrials.gov/show/NCT01033877 |
Completed |
Statens Serum Institut |
2010-08-31 |
| NCT01031303 |
Immunogenicity and Safety of TETRAXIMâ„¢ Given as a Booster Dose at 4 to 6 Years of Age |
https://ClinicalTrials.gov/show/NCT01031303 |
Completed |
Sanofi |
2010-09-30 |
| NCT00970307 |
Immunogenicity and Safety Study of GSK Biologicals’ GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age |
https://ClinicalTrials.gov/show/NCT00970307 |
Completed |
GlaxoSmithKline |
2010-01-27 |
| NCT00964028 |
Safety Study of GSK Biologicals’ DTPa-IPV/Hib (Infanrixâ„¢-IPV/Hib) |
https://ClinicalTrials.gov/show/NCT00964028 |
Completed |
GlaxoSmithKline |
2010-04-12 |
| NCT03870061 |
Evaluation of an Infant Immunization Encouragement Program in Nigeria |
https://ClinicalTrials.gov/show/NCT03870061 |
Completed |
GiveWell |
2020-02-20 |
| NCT00879827 |
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants |
https://ClinicalTrials.gov/show/NCT00879827 |
Completed |
GlaxoSmithKline |
2001-05-31 |
| NCT00871117 |
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years |
https://ClinicalTrials.gov/show/NCT00871117 |
Completed |
GlaxoSmithKline |
2010-01-15 |
| NCT00871000 |
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. |
https://ClinicalTrials.gov/show/NCT00871000 |
Completed |
GlaxoSmithKline |
2009-11-18 |
| NCT03208101 |
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults |
https://ClinicalTrials.gov/show/NCT03208101 |
Completed |
LG Chem |
2017-09-06 |
| NCT00831753 |
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants |
https://ClinicalTrials.gov/show/NCT00831753 |
Completed |
Sanofi |
2009-05-31 |
| NCT00831311 |
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants |
https://ClinicalTrials.gov/show/NCT00831311 |
Completed |
Sanofi |
2005-11-30 |
| NCT00802867 |
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ |
https://ClinicalTrials.gov/show/NCT00802867 |
Completed |
Sanofi |
2005-06-30 |
| NCT00777790 |
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents |
https://ClinicalTrials.gov/show/NCT00777790 |
Completed |
Sanofi |
2004-04-30 |
| NCT00777257 |
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine |
https://ClinicalTrials.gov/show/NCT00777257 |
Completed |
Sanofi |
2007-03-31 |
| NCT00772928 |
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacelâ„¢ |
https://ClinicalTrials.gov/show/NCT00772928 |
Completed |
Sanofi |
2006-05-31 |
| NCT00772070 |
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine |
https://ClinicalTrials.gov/show/NCT00772070 |
Completed |
Sanofi |
2003-08-31 |
| NCT00771849 |
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children |
https://ClinicalTrials.gov/show/NCT00771849 |
Completed |
Sanofi |
2004-03-31 |
| NCT00753649 |
Immunogenicity and Safety of GSK Biologicals’ Infanrix Hexa in Infants |
https://ClinicalTrials.gov/show/NCT00753649 |
Completed |
GlaxoSmithKline |
2013-03-12 |
| NCT00715234 |
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients |
https://ClinicalTrials.gov/show/NCT00715234 |
Completed |
University of Colorado, Denver |
2009-12-31 |
| NCT00712959 |
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose |
https://ClinicalTrials.gov/show/NCT00712959 |
Completed |
Sanofi |
2009-09-30 |
| NCT00707148 |
Pertussis Vaccine in Healthy Pregnant Women |
https://ClinicalTrials.gov/show/NCT00707148 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2012-05-31 |
| NCT00696423 |
Immunogenicity and Safety of GSK Biologicals’ Infanrix/Hib in Children |
https://ClinicalTrials.gov/show/NCT00696423 |
Completed |
GlaxoSmithKline |
2008-07-26 |
| NCT00674908 |
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine |
https://ClinicalTrials.gov/show/NCT00674908 |
Completed |
Shantha Biotechnics Limited |
2009-03-31 |
| NCT00662870 |
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine |
https://ClinicalTrials.gov/show/NCT00662870 |
Completed |
Sanofi |
2004-01-31 |
| NCT00654901 |
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexaâ„¢ |
https://ClinicalTrials.gov/show/NCT00654901 |
Completed |
Sanofi |
2009-05-31 |
| NCT00643916 |
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age |
https://ClinicalTrials.gov/show/NCT00643916 |
Completed |
Sanofi |
2006-03-31 |
| NCT00635128 |
Safety and Immunogenicity of a Booster Dose of GSK Biological’s Boostrix-Polio Vaccine |
https://ClinicalTrials.gov/show/NCT00635128 |
Completed |
GlaxoSmithKline |
2008-07-08 |
| NCT00627458 |
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio’s DTPa-HBV-IPV/Hib Vaccine |
https://ClinicalTrials.gov/show/NCT00627458 |
Completed |
GlaxoSmithKline |
2008-08-18 |
| NCT00619502 |
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants |
https://ClinicalTrials.gov/show/NCT00619502 |
Completed |
Sanofi |
2008-07-31 |
| NCT00617812 |
Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine |
https://ClinicalTrials.gov/show/NCT00617812 |
Completed |
Shantha Biotechnics Limited |
2009-04-30 |
| NCT00611559 |
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children |
https://ClinicalTrials.gov/show/NCT00611559 |
Completed |
GlaxoSmithKline |
2008-06-25 |
| NCT00610168 |
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. |
https://ClinicalTrials.gov/show/NCT00610168 |
Completed |
GlaxoSmithKline |
2008-04-30 |
| NCT00601835 |
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td |
https://ClinicalTrials.gov/show/NCT00601835 |
Completed |
Sanofi |
2005-07-31 |
| NCT00548171 |
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 |
https://ClinicalTrials.gov/show/NCT00548171 |
Completed |
GlaxoSmithKline |
2008-04-30 |
| NCT00534833 |
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hibâ„¢ |
https://ClinicalTrials.gov/show/NCT00534833 |
Completed |
Sanofi |
2008-09-30 |
| NCT00514709 |
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants |
https://ClinicalTrials.gov/show/NCT00514709 |
Completed |
Sanofi |
2008-12-31 |
| NCT00514059 |
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine |
https://ClinicalTrials.gov/show/NCT00514059 |
Completed |
Norwegian Institute of Public Health |
NA |
| NCT00473668 |
Non-inferiority of GSK Biologicals’ DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals’ DTPw-HBV/Hib |
https://ClinicalTrials.gov/show/NCT00473668 |
Completed |
GlaxoSmithKline |
2008-01-30 |
| NCT00467519 |
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age |
https://ClinicalTrials.gov/show/NCT00467519 |
Completed |
Sanofi |
2009-11-30 |
| NCT00463437 |
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines |
https://ClinicalTrials.gov/show/NCT00463437 |
Completed |
GlaxoSmithKline |
2008-01-21 |
| NCT00457249 |
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older |
https://ClinicalTrials.gov/show/NCT00457249 |
Completed |
Sanofi |
2008-09-30 |
| NCT00453570 |
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months |
https://ClinicalTrials.gov/show/NCT00453570 |
Completed |
Sanofi |
2008-12-31 |
| NCT00447525 |
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children |
https://ClinicalTrials.gov/show/NCT00447525 |
Completed |
Sanofi |
2008-01-31 |
| NCT00432042 |
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) |
https://ClinicalTrials.gov/show/NCT00432042 |
Completed |
Merck Sharp & Dohme Corp. |
2008-03-27 |
| NCT00412854 |
Study to Assess Safety & Immunogenicity of GSK Biologicals’ DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. |
https://ClinicalTrials.gov/show/NCT00412854 |
Completed |
GlaxoSmithKline |
2007-06-01 |
| NCT00406562 |
Study to Assess the Safety & Reactogenicity of GSK Biologicals’ dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. |
https://ClinicalTrials.gov/show/NCT00406562 |
Completed |
GlaxoSmithKline |
NA |
| NCT00404651 |
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00404651 |
Completed |
Sanofi |
2008-04-30 |
| NCT00401531 |
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants |
https://ClinicalTrials.gov/show/NCT00401531 |
Completed |
Sanofi |
2007-11-30 |
| NCT00379977 |
Study to Assess the Safety & Reactogenicity of GSK Biologicals’ DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age |
https://ClinicalTrials.gov/show/NCT00379977 |
Completed |
GlaxoSmithKline |
NA |
| NCT00376779 |
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age |
https://ClinicalTrials.gov/show/NCT00376779 |
Completed |
GlaxoSmithKline |
2007-05-31 |
| NCT00362427 |
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® |
https://ClinicalTrials.gov/show/NCT00362427 |
Completed |
Sanofi |
2009-02-28 |
| NCT00362336 |
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV |
https://ClinicalTrials.gov/show/NCT00362336 |
Completed |
Sanofi |
2008-05-31 |
| NCT00355121 |
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® |
https://ClinicalTrials.gov/show/NCT00355121 |
Completed |
Sanofi |
2009-06-30 |
| NCT00352963 |
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). |
https://ClinicalTrials.gov/show/NCT00352963 |
Completed |
GlaxoSmithKline |
NA |
| NCT00348881 |
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hibâ„¢, Concomitantly With OPV in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00348881 |
Completed |
Sanofi |
2007-10-31 |
| NCT00347958 |
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine |
https://ClinicalTrials.gov/show/NCT00347958 |
Completed |
Sanofi |
2008-02-29 |
| NCT00346073 |
Safety and Immunogenicity of GSK’s Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
https://ClinicalTrials.gov/show/NCT00346073 |
Completed |
GlaxoSmithKline |
2007-03-01 |
| NCT00343889 |
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hibâ„¢, Both Given Concomitantly With Oral Polio Vaccine |
https://ClinicalTrials.gov/show/NCT00343889 |
Completed |
Sanofi |
2007-11-30 |
| NCT00343421 |
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers |
https://ClinicalTrials.gov/show/NCT00343421 |
Completed |
Sanofi |
2008-06-30 |
| NCT00337428 |
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00337428 |
Completed |
Merck Sharp & Dohme Corp. |
2007-05-31 |
| NCT00332566 |
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib |
https://ClinicalTrials.gov/show/NCT00332566 |
Completed |
GlaxoSmithKline |
2006-10-31 |
| NCT00325156 |
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00325156 |
Completed |
GlaxoSmithKline |
2007-08-23 |
| NCT00325143 |
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine |
https://ClinicalTrials.gov/show/NCT00325143 |
Completed |
GlaxoSmithKline |
2007-02-01 |
| NCT00325130 |
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) |
https://ClinicalTrials.gov/show/NCT00325130 |
Completed |
Merck Sharp & Dohme Corp. |
2007-04-30 |
| NCT00320463 |
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00320463 |
Completed |
GlaxoSmithKline |
NA |
| NCT00319852 |
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV |
https://ClinicalTrials.gov/show/NCT00319852 |
Completed |
Sanofi |
2008-04-30 |
| NCT00317187 |
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. |
https://ClinicalTrials.gov/show/NCT00317187 |
Completed |
GlaxoSmithKline |
2005-01-16 |
| NCT00317174 |
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. |
https://ClinicalTrials.gov/show/NCT00317174 |
Completed |
GlaxoSmithKline |
NA |
| NCT00317161 |
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. |
https://ClinicalTrials.gov/show/NCT00317161 |
Completed |
GlaxoSmithKline |
2005-04-30 |
| NCT00317135 |
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. |
https://ClinicalTrials.gov/show/NCT00317135 |
Completed |
GlaxoSmithKline |
2004-10-23 |
| NCT00317122 |
Assess the Immune Response Following Primary Vaccination With GSK Biologicals’ Tritanrixâ„¢-HepB/Hib-MenAC vs Tritanrixâ„¢-HepB/Hiberixâ„¢ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth |
https://ClinicalTrials.gov/show/NCT00317122 |
Completed |
GlaxoSmithKline |
2005-07-31 |
| NCT00316147 |
Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules |
https://ClinicalTrials.gov/show/NCT00316147 |
Completed |
GlaxoSmithKline |
NA |
| NCT00315055 |
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule |
https://ClinicalTrials.gov/show/NCT00315055 |
Completed |
Sanofi |
2007-07-31 |
| NCT00313911 |
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hibâ„¢ and OPV Given at Age 2, 4, and 6 Months. |
https://ClinicalTrials.gov/show/NCT00313911 |
Completed |
Sanofi |
2008-01-31 |
| NCT00307567 |
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 |
https://ClinicalTrials.gov/show/NCT00307567 |
Completed |
GlaxoSmithKline |
NA |
| NCT00304265 |
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine |
https://ClinicalTrials.gov/show/NCT00304265 |
Completed |
Sanofi |
2006-10-31 |
| NCT00303316 |
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIMâ„¢ at 18 Months in Healthy Argentinean Infants |
https://ClinicalTrials.gov/show/NCT00303316 |
Completed |
Sanofi |
2007-04-30 |
| NCT00291967 |
Assess Immune Response Following Primary Vaccination With Tritanrixâ„¢-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants |
https://ClinicalTrials.gov/show/NCT00291967 |
Completed |
GlaxoSmithKline |
NA |
| NCT00290342 |
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants |
https://ClinicalTrials.gov/show/NCT00290342 |
Completed |
GlaxoSmithKline |
2007-01-01 |
| NCT00290303 |
Assess if Immune Response of GSK Biologicals’ Tritanrixâ„¢-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrixâ„¢-HepB/Hiberixâ„¢ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants |
https://ClinicalTrials.gov/show/NCT00290303 |
Completed |
GlaxoSmithKline |
2005-03-31 |
| NCT00287092 |
Comparison of Safety and Immunogenicity of Pediacelâ„¢ and Infanrixâ„¢ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants |
https://ClinicalTrials.gov/show/NCT00287092 |
Completed |
Sanofi |
2007-05-31 |
| NCT00282295 |
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease |
https://ClinicalTrials.gov/show/NCT00282295 |
Completed |
GlaxoSmithKline |
2006-08-08 |
| NCT00263692 |
Comparison of GSK Biologicals’ DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety |
https://ClinicalTrials.gov/show/NCT00263692 |
Completed |
GlaxoSmithKline |
2004-09-30 |
| NCT00263679 |
Assessment of GSK Biologicals’ Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. |
https://ClinicalTrials.gov/show/NCT00263679 |
Completed |
GlaxoSmithKline |
2004-05-31 |
| NCT00259337 |
Immunogenicity and Safety of Pentaximâ„¢ in an Indian Population |
https://ClinicalTrials.gov/show/NCT00259337 |
Completed |
Sanofi |
2008-04-30 |
| NCT00258908 |
Immunogenicity and Safety of ADACELâ„¢ as Fifth Dose in Taiwan |
https://ClinicalTrials.gov/show/NCT00258908 |
Completed |
Sanofi |
2006-08-31 |
| NCT00258895 |
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® |
https://ClinicalTrials.gov/show/NCT00258895 |
Completed |
Sanofi |
2006-12-31 |
| NCT00255047 |
Safety and Immune Response of Different Pediatric Combination Vaccines. |
https://ClinicalTrials.gov/show/NCT00255047 |
Completed |
Sanofi |
2008-07-31 |
| NCT00255021 |
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand |
https://ClinicalTrials.gov/show/NCT00255021 |
Completed |
Sanofi |
2007-09-30 |
| NCT00254969 |
Immunogenicity and Safety of Pentaxim in South African Infants |
https://ClinicalTrials.gov/show/NCT00254969 |
Completed |
Sanofi |
2008-05-31 |
| NCT00254917 |
Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines |
https://ClinicalTrials.gov/show/NCT00254917 |
Completed |
Sanofi |
2006-02-28 |
| NCT00244673 |
Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination |
https://ClinicalTrials.gov/show/NCT00244673 |
Completed |
Bandim Health Project |
2011-12-31 |
| NCT00228917 |
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children |
https://ClinicalTrials.gov/show/NCT00228917 |
Completed |
GlaxoSmithKline |
2006-01-20 |
| NCT00197275 |
Lot-to-lot Consistency of Tritanrixâ„¢-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrixâ„¢-HepB/Hiberixâ„¢ in Infants |
https://ClinicalTrials.gov/show/NCT00197275 |
Completed |
GlaxoSmithKline |
NA |
| NCT02477995 |
Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants |
https://ClinicalTrials.gov/show/NCT02477995 |
Completed |
Jiangsu Province Centers for Disease Control and Prevention |
2014-05-31 |
| NCT00169442 |
Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants |
https://ClinicalTrials.gov/show/NCT00169442 |
Completed |
GlaxoSmithKline |
2006-03-01 |
| NCT00168545 |
Immunology of Non-specific Effects of Vaccine |
https://ClinicalTrials.gov/show/NCT00168545 |
Completed |
Bandim Health Project |
NA |
| NCT00164411 |
Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine |
https://ClinicalTrials.gov/show/NCT00164411 |
Completed |
Centers for Disease Control and Prevention |
NA |
| NCT00158808 |
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths |
https://ClinicalTrials.gov/show/NCT00158808 |
Completed |
GlaxoSmithKline |
2005-04-30 |
| NCT00148941 |
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals’ DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines |
https://ClinicalTrials.gov/show/NCT00148941 |
Completed |
GlaxoSmithKline |
2006-11-01 |
| NCT00136604 |
Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m |
https://ClinicalTrials.gov/show/NCT00136604 |
Completed |
GlaxoSmithKline |
2006-04-23 |
| NCT00133445 |
Pentavalent DTaP-Hep B-IPV |
https://ClinicalTrials.gov/show/NCT00133445 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-08-31 |
| NCT00109330 |
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine |
https://ClinicalTrials.gov/show/NCT00109330 |
Completed |
GlaxoSmithKline |
2004-04-30 |
| NCT00092469 |
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00092469 |
Completed |
Merck Sharp & Dohme Corp. |
2003-08-31 |
| NCT00797511 |
Immunogenicity and Safety of Adacel Polio Vaccine |
https://ClinicalTrials.gov/show/NCT00797511 |
Completed |
Sanofi |
2009-04-30 |
| NCT00319553 |
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® |
https://ClinicalTrials.gov/show/NCT00319553 |
Completed |
Sanofi |
2008-10-31 |
| NCT00489970 |
Persistence Study of GSK Biologicals’ Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
https://ClinicalTrials.gov/show/NCT00489970 |
Completed |
GlaxoSmithKline |
2011-09-01 |
| NCT00385255 |
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults |
https://ClinicalTrials.gov/show/NCT00385255 |
Completed |
GlaxoSmithKline |
2007-02-28 |